CLINICAL RESEARCH: HEART FAILURE
Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy
Denis Duboc, MD, PhD*,*,
Christophe Meune, MD*,
Guy Lerebours, MD ,
Jean-Yves Devaux, MD, PhD*,
Guy Vaksmann, MD* and
Henri-Marc Bécane, MD*
* French Working Group of Heart Involvement in Myopathies Investigators, Paris, France
Servier Laboratories, Paris, France
Manuscript received March 2, 2004;
revised manuscript received August 5, 2004,
accepted September 13, 2004.
* Reprint requests and correspondence: Dr. Denis Duboc, Department of Cardiology, Cochin Hospital, 27 rue du Faubourg St-Jacques, 75014 Paris, France
(Email: denis.duboc{at}cch.ap-hop-paris.fr).
OBJECTIVES: The aim of this research was to examine the effects of perindopril on cardiac function in patients with Duchenne muscular dystrophy (DMD).
BACKGROUND: Duchenne muscular dystrophy, an inherited X-linked disease, is characterized by progressive muscle weakness and myocardial involvement.
METHODS: In phase I, 57 children with DMD and a left ventricular ejection fraction (LVEF) >55% (mean 65.0 ± 5.4%), 9.5 to 13 years of age (mean 10.7 ± 1.2 years), were enrolled in a three-year multicenter, randomized, double-blind trial of perindopril, 2 to 4 mg/day (group 1), versus placebo (group 2). In phase II, all patients received open-label perindopril for 24 more months; LVEF was measured at 0, 36, and 60 months.
RESULTS: Phase I was completed by 56 (27 in group 1 and 29 in group 2) and phase II by 51 patients (24 in group 1 and 27 in group 2). There was no difference in baseline characteristics between the treatment groups. At the end of phase I, mean LVEF was 60.7 ± 7.6% in group 1 versus 64.4 ± 9.8% in group 2, and was <45% in a single patient in each group (p = NS). At 60 months, LVEF was 58.6 ± 8.1% in group 1 versus 56.0 ± 15.5% in group 2 (p = NS). A single patient had an LVEF <45% in group 1 versus eight patients in group 2 (p = 0.02).
CONCLUSIONS: Early treatment with perindopril delayed the onset and progression of prominent left ventricle dysfunction in children with DMD.
|
Abbreviations and Acronyms
| | ACEI = angiotensin-converting enzyme inhibitors | | CHF = congestive heart failure | | DMD = Duchenne muscular dystrophy | | LV = left ventricle/ventricular | | LVEF = left ventricular ejection fraction |
|
Related Article
-
Did they lower stress in the trial?: Or was it just wasted energy?
- Stephen P. Sanders
J. Am. Coll. Cardiol. 2005 45: 858-859.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Bauer, V. Straub, A. Blain, K. Bushby, and G. A. MacGowan
Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy
Eur J Heart Fail,
May 1, 2009;
11(5):
463 - 471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Pasquali, M. Hall, A. D. Slonim, K. J. Jenkins, B. S. Marino, M. S. Cohen, and S. S. Shah
Off-Label Use of Cardiovascular Medications in Children Hospitalized With Congenital and Acquired Heart Disease
Circ Cardiovasc Qual Outcomes,
November 1, 2008;
1(2):
74 - 83.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Y Manzur, M Kinali, and F Muntoni
Update on the management of Duchenne muscular dystrophy
Arch. Dis. Child.,
November 1, 2008;
93(11):
986 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M McNally
Duchenne muscular dystrophy: how bad is the heart?
Heart,
August 1, 2008;
94(8):
976 - 977.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.P. Beynon and S.G. Ray
Cardiac involvement in muscular dystrophies
QJM,
May 1, 2008;
101(5):
337 - 344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Duboc, C. Meune, B. Pierre, K. Wahbi, B. Eymard, A. Toutain, C. Berard, G. Vaksmann, and H.-M. Becane
Perindopril preserves left ventricular function in X-linked Duchenne muscular dystrophy
Eur. Heart J. Suppl.,
September 1, 2007;
9(suppl_E):
E20 - E24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Silva, Z. M. A. Meira, J. Gurgel Giannetti, M. M. da Silva, A. F. Oliveira Campos, M. de Melo Barbosa, G. M. S. Filho, R. de Aguiar Ferreira, M. Zatz, and C. E. Rochitte
Myocardial Delayed Enhancement by Magnetic Resonance Imaging in Patients With Muscular Dystrophy
J. Am. Coll. Cardiol.,
May 8, 2007;
49(18):
1874 - 1879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Simonds
Recent Advances in Respiratory Care for Neuromuscular Disease
Chest,
December 1, 2006;
130(6):
1879 - 1886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Danford
Steroid Treatment for Cardiac Function in Duchenne Muscular Dystrophy
AAP Grand Rounds,
May 1, 2006;
15(5):
58 - 59.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Cripe and L. Markham
Therapeutic Nihilism in Duchenne Cardiomyopathy: In Reply
Pediatrics,
May 1, 2006;
117(5):
1865 - 1865.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Stollberger and J. Finsterer
Can Perindopril Delay the Onset of Heart Failure in Duchenne Muscular Dystrophy?
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1781 - 1781.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Meune and D. Duboc
Reply
J. Am. Coll. Cardiol.,
November 1, 2005;
46(9):
1782 - 1782.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Colan
Evolving Therapeutic Strategies for Dystrophinopathies: Potential for Conflict Between Cardiac and Skeletal Needs
Circulation,
November 1, 2005;
112(18):
2756 - 2758.
[Full Text]
[PDF]
|
|
|
|
